Building on frameworks developed for PD-L1, other immune checkpoint markers such as B7-H3, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and Lymphocyte Activation Gene 3 (LAG-3), along with VISTA, are also under active research as potential predictive biomarkers for immunotherapy response in renal cancers, as well as bladder cancers [115,116,117,122,123]. The gene discussed is LAG3; the disease is urinary bladder carcinoma.